191 related articles for article (PubMed ID: 34665339)
21. Approach to the Patient with Recurrent/Metastatic Disease.
Guigay J; Sâada-Bouzid E; Peyrade F; Michel C
Curr Treat Options Oncol; 2019 Jun; 20(8):65. PubMed ID: 31240480
[TBL] [Abstract][Full Text] [Related]
22. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostics and therapy of pancreatic carcinoma].
Wenzel P; von Figura G
Dtsch Med Wochenschr; 2021 Feb; 146(4):246-252. PubMed ID: 33592660
[TBL] [Abstract][Full Text] [Related]
24. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
25. Treatment Paradigms for Older Adults with Pancreatic Cancer: a Nuanced Approach.
Winer A; Dotan E
Curr Treat Options Oncol; 2021 Oct; 22(11):104. PubMed ID: 34596801
[TBL] [Abstract][Full Text] [Related]
26. Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?
Novotny JP; George S
Curr Treat Options Oncol; 2021 Sep; 22(11):99. PubMed ID: 34524549
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy for pancreatic cancer.
Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
[TBL] [Abstract][Full Text] [Related]
28. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic cancer.
Mizrahi JD; Surana R; Valle JW; Shroff RT
Lancet; 2020 Jun; 395(10242):2008-2020. PubMed ID: 32593337
[TBL] [Abstract][Full Text] [Related]
30. Promising New Agents for Colorectal Cancer.
Das S; Ciombor KK; Haraldsdottir S; Goldberg RM
Curr Treat Options Oncol; 2018 May; 19(6):29. PubMed ID: 29752549
[TBL] [Abstract][Full Text] [Related]
31. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
32. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
34. Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Gao J; Wang J; Guan C; Shi W; Dong Q; Sheng J; Zou X; Xu Z; Ge Y; Huang Z; Li J; Bao H; Xu Y; Cui Y; Xu X; Zhong X
J Cancer; 2024; 15(8):2214-2228. PubMed ID: 38495490
[TBL] [Abstract][Full Text] [Related]
35. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
36. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
Frigerio I; Regi P; Giardino A; Scopelliti F; Girelli R; Bassi C; Gobbo S; Martini PT; Capelli P; D'Onofrio M; Malleo G; Maggino L; Viviani E; Butturini G
Ann Surg Oncol; 2017 Aug; 24(8):2397-2403. PubMed ID: 28516291
[TBL] [Abstract][Full Text] [Related]
37. Choice of first line systemic treatment in pancreatic cancer among national experts.
Glatzer M; Horber D; Montemurro M; Winterhalder R; Inauen R; Berger MD; Pestalozzi B; Pederiva S; Pless M; Putora PM
Pancreatology; 2020 Jun; 20(4):686-690. PubMed ID: 32299764
[TBL] [Abstract][Full Text] [Related]
38. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
Rubinson DA; Wolpin BM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
Ma ZY; Gong YF; Zhuang HK; Zhou ZX; Huang SZ; Zou YP; Huang BW; Sun ZH; Zhang CZ; Tang YQ; Hou BH
World J Gastroenterol; 2020 May; 26(19):2305-2322. PubMed ID: 32476795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]